Why the study?
Does genotype-guided warfarin dosing improve cost-effectiveness compared to standard induction in patients with nonvalvular atrial fibrillation?
Population
Outpatients or inpatients requiring initiation of warfarin therapy. The base case was a man age 69 years…
Comparison
Genotype-guided dosing consisting of genotyping… vs Standard warfarin induction
Design
Other
Follow-up
Lifetime
Authors
Loading...
Genotype-guided warfarin dosing should not change practice in typical nonvalvular AF; leaves open targeted evaluation in high-hemorrhage-risk subgroups.
Does genotype-guided warfarin dosing improve cost-effectiveness compared to standard induction in patients with nonvalvular atrial fibrillation?
Genotype-guided warfarin dosing is unlikely to be cost-effective for typical patients with nonvalvular atrial fibrillation, though it may be cost-effective for those at high risk of hemorrhage.
Mark H. Eckman (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: